With Second Mevion Proton System Installed at Siteman Cancer Center, Additional Cancer Patients Begin Treatment

IN.PACT AV Drug-Coated Balloon Is First and Only to Show Superior and Sustained Results Through Two Years Compared to PTA in Treating Arteriovenous Fistulae Lesions

The data, which were presented virtually as a podium first at the 2021 Charing Cross Symposium, demonstrated that the IN.PACT™ AV drug-coated balloon (DCB) is the first and only DCB to show sustained and superior effectiveness through two years compared to standard percutaneous transluminal angioplasty (PTA) in end-stage renal disease (ESRD) patients with de novo or non-stented restenotic native arteriovenous fistulae (AVF) in the upper extremity.

Martell Diagnostic Laboratories Announces HERTEST: Groundbreaking Way to Detect Effectiveness of Breast Cancer RX Globally

HERTEST is a blood test that looks for a protein called human epidermal growth factor receptor (HER2), which is shed into the blood stream of patients with growing breast cancer tumors.

ESPRIT CAM Improves Productivity for Long Part Machining by Automating Multi-spindle Program Creation

ESPRIT CAM: New computer-aided-manufacturing (CAM) technology has been introduced by ESPRIT CAM, part of Hexagon’s Manufacturing Intelligence division that provides manufacturers with the control and flexibility needed to use multi-spindle and multi-channel computer-numerical-control (CNC) machinery for the machining of long parts.

Mevion Medical Systems announced today that patient treatment has commenced on the MEVION S250i Proton Therapy System® at the S. Lee Kling Proton Therapy Center at Siteman Cancer Center, based at Washington University School of Medicine and Barnes-Jewish Hospital in St. Louis. The new proton therapy system is located directly next to the first system, which was installed in 2013. Mevion is the only proton therapy provider capable of offering a truly modular room-by-room or 1+1 expansion.

Siteman Cancer Center, an NCI-designated Comprehensive Cancer Center, serves patients in Missouri, Southern Illinois, and beyond. Each year, hundreds of cancer patients treated at Siteman have received proton therapy, which is used to treat lung, brain, head and neck, gastrointestinal and gynecologic cancers, and other difficult-to-treat tumors. The growing number of patients treated with proton therapy has increased the need for a second system to accommodate demand.

The newest addition to the Kling Proton Center features Mevion’s industry-leading HYPERSCAN® technology and Adaptive Aperture® pMLC. HYPERSCAN provides faster and more precise targeted dose delivery to tumors and minimizes the damage to surrounding healthy tissue and sensitive organs at risk. Siteman has also integrated a high-resolution ceiling-mounted cone-beam CT system and a diagnostic CT on-rail system, enabling a state-of-art Image-Guided Proton Therapy (IGPT) configuration allowing their team to provide adaptive and hypofractionated proton therapy.

“During the past seven years, we have incorporated proton therapy into the treatment plans for hundreds of adult and pediatric cancer patients. Our ability to expand with a second system will enable us to continue to offer the latest technology to more patients and to expand the clinical use of proton therapy,” said Stephanie Perkins, M.D., director, S. Lee Kling Proton Therapy Center.

Scientists from Siteman and Mevion’s Advanced Development team have collaborated on ultra-high dose rate, FLASH therapy research. Last fall, the group successfully delivered over 200Gy/s dose rate on a Mevion production system and published a joint research paper in Medical Physics this May.

“We congratulate Siteman for starting treatment with their second Mevion system,” said Tina Yu, chief executive officer of Mevion Medical Systems. “Mevion is proud to deepen our collaboration with Siteman and look forward to discussing and developing next-generation technology and treatment protocols to expand the use of proton therapy on both systems.”

spot_img

DON'T MISS

Related Articles